Treatment of MCL Granta-519 cells with BSJ-02–162 resulted in the loss of CDK4/6 and IKZF1/3 proteins and showed increased antiproliferative effects compared to palbociclib or lenalidomide alone, suggesting that co-targeting CDK4/6 and IKZF1/3 may be an effective strategy for treating MCL. Here, IKZF1 is linked to mantle cell lymphoma.